Cargando…
Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have MASLD, and, at the same time, the presence of MASLD increases the risk of diabetes by more than two times. Type 2 diabet...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534491/ https://www.ncbi.nlm.nih.gov/pubmed/37764998 http://dx.doi.org/10.3390/ph16091190 |
_version_ | 1785112406954868736 |
---|---|
author | Hachuła, Marcin Kosowski, Michał Basiak, Marcin Okopień, Bogusław |
author_facet | Hachuła, Marcin Kosowski, Michał Basiak, Marcin Okopień, Bogusław |
author_sort | Hachuła, Marcin |
collection | PubMed |
description | Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have MASLD, and, at the same time, the presence of MASLD increases the risk of diabetes by more than two times. Type 2 diabetes and MASLD are independent cardiovascular disease (CVD) risk factors. New diabetes treatment should also take into account pleiotropic effects that reduce cardiovascular risk. The aim of our study is to investigate whether analogs of GLP1 receptors have a pleiotropic metabolic effect and global impact to decrease cardiovascular risk, and also reduce the risk of hepatic fibrosis in patients with MASLD. This study involved 41 patients with diabetes and dyslipidemia who also had atherosclerotic plaque and hepatic steatosis verified by ultrasonography and who were eligible to begin one of the GLP1 receptor agonists treatments. We observed a statistically significant decrease in: BMI (p < 0.001) waist and hip circumference (p < 0.001), glycated hemoglobin (p < 0.001) and creatinine (p < 0.05). Additionally, we obtained a decrease in FIB-4 (p < 0.001) and in the De Ritis (AST/ALT aminotransferase ratio) (p < 0.05). The positive correlation between the FIB-4 value and BMI, WHR, waist circumference and the De Ritis index was observed. In conclusion, semaglutide and dulaglutide had a beneficial effect on metabolic and cardiovascular risk factors in patients with type 2 diabetes. These medications had a positive effect on MASLD biochemical markers. |
format | Online Article Text |
id | pubmed-10534491 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105344912023-09-29 Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study Hachuła, Marcin Kosowski, Michał Basiak, Marcin Okopień, Bogusław Pharmaceuticals (Basel) Article Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is associated with the excessive collection of lipids in hepatocytes. Over 75% of diabetes patients typically have MASLD, and, at the same time, the presence of MASLD increases the risk of diabetes by more than two times. Type 2 diabetes and MASLD are independent cardiovascular disease (CVD) risk factors. New diabetes treatment should also take into account pleiotropic effects that reduce cardiovascular risk. The aim of our study is to investigate whether analogs of GLP1 receptors have a pleiotropic metabolic effect and global impact to decrease cardiovascular risk, and also reduce the risk of hepatic fibrosis in patients with MASLD. This study involved 41 patients with diabetes and dyslipidemia who also had atherosclerotic plaque and hepatic steatosis verified by ultrasonography and who were eligible to begin one of the GLP1 receptor agonists treatments. We observed a statistically significant decrease in: BMI (p < 0.001) waist and hip circumference (p < 0.001), glycated hemoglobin (p < 0.001) and creatinine (p < 0.05). Additionally, we obtained a decrease in FIB-4 (p < 0.001) and in the De Ritis (AST/ALT aminotransferase ratio) (p < 0.05). The positive correlation between the FIB-4 value and BMI, WHR, waist circumference and the De Ritis index was observed. In conclusion, semaglutide and dulaglutide had a beneficial effect on metabolic and cardiovascular risk factors in patients with type 2 diabetes. These medications had a positive effect on MASLD biochemical markers. MDPI 2023-08-22 /pmc/articles/PMC10534491/ /pubmed/37764998 http://dx.doi.org/10.3390/ph16091190 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hachuła, Marcin Kosowski, Michał Basiak, Marcin Okopień, Bogusław Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study |
title | Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study |
title_full | Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study |
title_fullStr | Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study |
title_full_unstemmed | Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study |
title_short | Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study |
title_sort | does therapy with glucagon-like peptide 1 receptor agonists have an effect on biochemical markers of metabolic-dysfunction-associated steatotic liver disease (masld)? pleiotropic metabolic effect of novel antidiabetic drugs in patients with diabetes—interventional study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534491/ https://www.ncbi.nlm.nih.gov/pubmed/37764998 http://dx.doi.org/10.3390/ph16091190 |
work_keys_str_mv | AT hachułamarcin doestherapywithglucagonlikepeptide1receptoragonistshaveaneffectonbiochemicalmarkersofmetabolicdysfunctionassociatedsteatoticliverdiseasemasldpleiotropicmetaboliceffectofnovelantidiabeticdrugsinpatientswithdiabetesinterventionalstudy AT kosowskimichał doestherapywithglucagonlikepeptide1receptoragonistshaveaneffectonbiochemicalmarkersofmetabolicdysfunctionassociatedsteatoticliverdiseasemasldpleiotropicmetaboliceffectofnovelantidiabeticdrugsinpatientswithdiabetesinterventionalstudy AT basiakmarcin doestherapywithglucagonlikepeptide1receptoragonistshaveaneffectonbiochemicalmarkersofmetabolicdysfunctionassociatedsteatoticliverdiseasemasldpleiotropicmetaboliceffectofnovelantidiabeticdrugsinpatientswithdiabetesinterventionalstudy AT okopienbogusław doestherapywithglucagonlikepeptide1receptoragonistshaveaneffectonbiochemicalmarkersofmetabolicdysfunctionassociatedsteatoticliverdiseasemasldpleiotropicmetaboliceffectofnovelantidiabeticdrugsinpatientswithdiabetesinterventionalstudy |